PHE's Seabury and Sood Promote Development of Antimicrobial Drugs in Health Affairs Blog Commentary

As global health leaders gather in Berlin from May 19-20 for the first-ever G20 Health Ministers’ meeting, one of the main topics of discussion is expected to be how to best fight the threat of antimicrobial resistance (AMR). In a new Health Affairs blog post, PHE scientific advisors Seth Seabury and Neeraj Sood propose a new model for the development of antimicrobial drugs. Market entry awards, exclusivity extensions and priority review vouchers are all critical tools that the authors examine, weighing their strengths and weaknesses.

To read the complete blog, please click here.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.